NCNA Quote, Financials, Valuation and Earnings

Autolus Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -781.13%. NuCana PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -49.92%.

NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 183970.8%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 319.39%. Given that NuCana PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe NuCana PLC is more attractive than Autolus Therapeutics PLC.

NuCana PLC has a beta of 1.426, which suggesting that the stock is 42.561% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. NuCana PLC's net income of -$3.1M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, NuCana PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Bicycle Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -608.94%. NuCana PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -28.27%.

NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 183970.8%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $26.27 which suggests that it could grow by 253.13%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.

NuCana PLC has a beta of 1.426, which suggesting that the stock is 42.561% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.784%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $10M. NuCana PLC's net income of -$3.1M is higher than Bicycle Therapeutics PLC's net income of -$60.8M. Notably, NuCana PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 18.75x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 183970.8%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1939.08%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.

NuCana PLC has a beta of 1.426, which suggesting that the stock is 42.561% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$3.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 0.92x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Mereo BioPharma Group PLC's return on equity of --.

NuCana PLC has a consensus price target of $104.00, signalling upside risk potential of 183970.8%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.54 which suggests that it could grow by 162.6%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.

NuCana PLC has a beta of 1.426, which suggesting that the stock is 42.561% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.683%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. NuCana PLC's net income of -$3.1M is higher than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, NuCana PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.